FDA Clears PrecivityAD2 Blood Test for Alzheimer's in Adults as Young as 40

The FDA cleared C2N Diagnostics' PrecivityAD2 blood test for Alzheimer's detection in symptomatic adults as young as 40, lowering the approved age for clinical use and enabling earlier diagnosis via a scalable blood test. This expands the pool of trial-eligible participants for Alzheimer's studies and signals a shift in trial design and recruitment practices toward younger populations.

This Wire brief sits within Fusion42's coverage of Digital Health.